# A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

> **NCT07064122** · PHASE1 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 72 (estimated)

## Conditions studied

- Haematologic Neoplasms

## Interventions

- **DRUG:** AZD2962

## Key facts

- **NCT ID:** NCT07064122
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-03
- **Primary completion:** 2028-10-20
- **Final completion:** 2028-10-20
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07064122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07064122, "A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07064122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*